NKp46 has been associated with good prognosis in human NSCLC (owing to the formation or maintenance of tertiary lymphoid structures (TLS), release of IL-22, TNF-α, IL-8, and IL-2 and recognition of lung tumour cells and tumour-associated fibroblasts via the NKp44 receptor [174] (Table 1). This evidence concerns the gene IL22 and neoplasm.